Bristol Myers Squibb

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Retrieved on: 
Wednesday, March 20, 2024
Oncology, FDA, Health, General Health, Pharmaceutical, Biotechnology, Civil service commission, BMY, Progression-free survival, Patient, Multiple myeloma, Pi, Bristol Myers Squibb, Doctor of Philosophy, European, ODAC, European Commission, PFS, Immunotherapy, Immunomodulatory imide drug, Food, Pharmaceutical industry

Abecma is the first chimeric antigen receptor (CAR) T cell immunotherapy approved in the European Union (EU) for use in earlier lines of therapy for relapsed and refractory multiple myeloma.

Key Points: 
  • Abecma is the first chimeric antigen receptor (CAR) T cell immunotherapy approved in the European Union (EU) for use in earlier lines of therapy for relapsed and refractory multiple myeloma.
  • * In the EU, Abecma has maintained its Orphan Designation for the treatment of multiple myeloma.
  • With increased use of the three main classes of therapy as combination regimens, more patients are becoming triple-class exposed earlier in their treatment journey.
  • Abecma is also approved in the U.S. for adult patients with triple-class exposed relapsed or refractory multiple myeloma after four or more prior lines of therapy and approved in Great Britain and Israel for adult patients with triple-class exposed relapsed and refractory multiple myeloma after three or more prior lines of therapy.

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Retrieved on: 
Wednesday, March 20, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, HCC, Bristol Myers Squibb, OS, BMY, TKI, Ipilimumab, Patient, Checkmate, Sorafenib, Immunotherapy, Survival, Nivolumab, Pharmaceutical industry

The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib.

Key Points: 
  • The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib.
  • The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals identified.
  • “Advanced stage liver cancer patients remain in need of additional treatment options that may help improve survival,” said Dana Walker, M.D., M.S.C.E., vice president, global program lead, gastrointestinal and genitourinary cancers, Bristol Myers Squibb.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -9DW clinical trial.

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

Retrieved on: 
Monday, March 18, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Psychosis, Bristol Myers Squibb, Citigroup, Growth, Schizophrenia, Goldman Sachs, KarXT, EPS, Patient, Simpson Thacher & Bartlett, Acquisition, BMS, LLP, Therapy, GAAP, Covington & Burling, Bipolar I disorder, PDUFA, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
  • With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).
  • “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • Bristol Myers Squibb expects to offset the operational expenses of the transaction through continued disciplined resource allocation, cost efficiencies and portfolio prioritization.

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

Retrieved on: 
Monday, March 18, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, BMY, Psychosis, Bristol Myers Squibb, Citigroup, Growth, Schizophrenia, KarXT, Goldman Sachs, EPS, Patient, Neuroscience, Simpson Thacher & Bartlett, Acquisition, BMS, LLP, PRTC, Therapy, GAAP, Covington & Burling, Psychiatry, Bipolar I disorder, PDUFA, Pharmaceutical industry

The full text of the announcement from Bristol Myers Squibb is as follows:

Key Points: 
  • The full text of the announcement from Bristol Myers Squibb is as follows:
    Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience
    PRINCETON, N.J.-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
  • With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”).
  • “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Retrieved on: 
Tuesday, March 19, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Psoriasis, Partnership, Patient, Neuroscience, Travel, Dermatology, Plaque, Bristol Myers Squibb, Humour, DSM-IV codes, Empowerment, System, Skin, Multimedia, FDA, Pharmaceutical industry

Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?

Key Points: 
  • Award-winning actor Ted Danson, who lives with plaque psoriasis, teams up with Bristol Myers Squibb for the inspiring “ SO, Have You Found It?
  • View the full release here: https://www.businesswire.com/news/home/20240315988620/en/
    Actor Ted Danson and SOTYKTU patient Emily both living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “Navigating plaque psoriasis is both deeply personal and often challenging for many patients,” acknowledged Carlos Dortrait, senior vice president and general manager of U.S. Immunology and Neuroscience at Bristol Myers Squibb.
  • Many with plaque psoriasis find themselves altering their lifestyles, sometimes avoiding social situations and personal connections.

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Retrieved on: 
Friday, March 15, 2024
Biotechnology, FDA, Pharmaceutical, Health, Emory University, Multiple myeloma, BMY, Development, Survival, ASH, Disease, Oncology, Patient, FACP, Committee, EMA, Cell therapy, Bristol Myers Squibb, MD, Winship Cancer Institute, European Medicines Agency, Society, ODAC, CHMP, Food, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint of overall survival.
  • The recommendation from the ODAC will be considered by the FDA during its ongoing review of the supplemental Biologics License Application (sBLA) for Abecma for this patient population.
  • The FDA has not yet assigned a new target action date for review of the sBLA.
  • “With patients becoming triple-class exposed earlier in the multiple myeloma treatment paradigm, it is critical that new treatment options with the potential to improve long-term outcomes are available as early as possible,” said Sagar Lonial, MD, FACP, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University.

Diversity Research Institute to Honor Diversity First Top Companies for Diversity and their CEOs at the 20th Annual National Diversity & Leadership Conference in Dallas, TX

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Business, Human Resources, DEI (Diversity, Equity and Inclusion), Xerox, Kraft Heinz, Microsoft, Bath & Body Works, Hewlett-Packard, Rocket Mortgage, Intel, EBay, Kimberly-Clark, Bath, Conference, PG&E, The Walt Disney Company, Organization, TIAA, AES Corporation, Procter, Coca-Cola, Procter & Gamble, Uber, Health, Gilead Sciences, Edison International, Bank, Diversity, Bristol Myers Squibb, Shantanu Narayen, Avis Budget Group, Science, Rite Aid, CVS Health, Ulta Beauty, Verizon Communications, Conagra Brands, UPS, Science Applications International Corporation, BNY Mellon, DRI, Vertex Pharmaceuticals, Otis Worldwide, Omnicom Group, CDW, DEI

The companies to be honored were selected from the U.S. Fortune 500 Governance Report (2023) published by Diversity First and DRI last year.

Key Points: 
  • The companies to be honored were selected from the U.S. Fortune 500 Governance Report (2023) published by Diversity First and DRI last year.
  • The report evaluates the executive and board demographics of U.S. Fortune 500 companies.
  • It assesses racial/ethnic and gender demographics of each company according to 2019 U.S. Census Data, providing each company with a score and a ranking.
  • The DRI, in affiliation with Diversity First, lists the companies with the highest scores as Diversity First Top 50 Companies.

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Retrieved on: 
Friday, March 15, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, SLL, BMY, B-cell lymphoma, Chronic lymphocytic leukemia, CLL, Bone marrow, Caregiver, Patient, Lymphocytosis, City, CRS, Commercial, Bristol Myers Squibb, BTK, MRD, Cytokine release syndrome, Division, Drug resistance, Multimedia, Blood, Associate professor, Food, Pharmaceutical industry

Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • Please see the Important Safety Information section below, including Boxed WARNINGS for Breyanzi regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.
  • “For years, attempts to bring other CAR T cell therapies to patients with relapsed or refractory CLL or SLL met challenges and found little success.
  • After relapsing or becoming refractory to these therapies, patients have few options and poor outcomes, including lack of durable complete responses.

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

Retrieved on: 
Monday, March 11, 2024
Mental Health, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Internal medicine, Psychiatry, Caregiver, Physician, Diabetes, Patient, Neuroscience, Bristol Myers Squibb, Maha, Bioverativ, UnitedHealth Group, Pharmaceutical industry

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D.
  • to the company’s board of directors.
  • “Maha joins our Board at a pivotal moment for Alto, as we continue on our path and fulfill our ambition of redefining psychiatry with our precision pipeline in areas of persistent medical need,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto.
  • “Throughout her distinguished career, Maha has been dedicated to advancing patient care through more personalized approaches to treatment.

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, BMY, Webcast

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024.
  • Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m.
  • Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com .
  • ET on May 9, 2024, by dialing in the U.S. toll free 1-877-344-7529 or international +1 412-317-0088, conference code: 5034750.